Lindbrook Capital’s Sana Biotechnology SANA Stock Holding History

Lindbrook Capital’s Portfolio SANA Stock Details SANA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$5.57K	Buy	3,314 +2,413	+268%	+$6.75K	﹤0.01%	1909
2024 Q4	$1.47K	Buy	901 +810	+890%	+$2.42K	﹤0.01%	2391
2024 Q3	$379	Buy	+91	New	+$478	﹤0.01%	2727
2023 Q4	–	Sell	-922	Closed	-$3.57K	–	2808
2023 Q3	$3.57K	Buy	922 +130	+16%	+$699	﹤0.01%	1919
2023 Q2	$4.72K	Hold	792	–	–	﹤0.01%	1834
2023 Q1	$2.59K	Buy	+792	New	+$3.16K	﹤0.01%	2133
2022 Q4	–	Sell	-234	Closed	-$1K	–	2985
2022 Q3	$1K	Buy	+234	New	+$1.69K	﹤0.01%	2472

Other funds holding SANA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lindbrook Capital's SANA Position: Q1 2025 in Review

Lindbrook Capital increased its Sana Biotechnology (SANA) stake by 268% in Q1 2025, buying an estimated $6.75K and bringing the position to 3,314 shares worth $5.57K. The position accounts for ﹤0.01% of the portfolio, ranked #1909.

Lindbrook Capital first reported a position in SANA in Q3 2022 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold SANA as of Q1 2025.

Lindbrook Capital held 3,314 shares of Sana Biotechnology worth $5.57K as of Q1 2025.
Lindbrook Capital bought 2,413 Sana Biotechnology shares in Q1 2025, an estimated $6.75K.
Sana Biotechnology made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1909 holding.
Lindbrook Capital first reported a position in Sana Biotechnology in Q3 2022 and has held it in 7 quarters since.
161 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.